Reactions to Allergy Shots: How They Change Over Your Treatment

No — the opposite is typically true. Reactions to allergy shots are most frequent during the build-up phase when doses are escalating, and they become less common as the maintenance phase is established. This is because IgG4 blocking antibodies accumulate progressively during treatment, raising the threshold for mast cell activation so that the same dose becomes better tolerated over time. The AAAAI/ACAAI surveillance data confirm that 70 to 80% of all systemic reactions occur during build-up. Once patients reach and stabilize at their maintenance dose, per-injection reaction rates decline substantially. However, there are exceptions: reactions can temporarily increase during peak pollen season (due to additive allergen burden), at new vial transitions, or if a patient's asthma becomes less controlled.

Not necessarily. Local injection-site reactions — redness, swelling, itching — are considered a normal part of SCIT and may actually reflect the immune system encountering the allergen dose. Mild systemic reactions during build-up are a recognized part of dose escalation and do not indicate treatment failure. They do tell the allergist that the current dose has exceeded your temporary tolerance threshold, which guides dose adjustment. Importantly, studies have not conclusively shown that patients who react more have worse outcomes — the AAAAI/ACAAI Practice Parameter notes that patients who experience systemic reactions typically continue treatment successfully after dose reduction and re-escalation. A 'tolerated maintenance dose' that is somewhat lower than the protocol target still confers meaningful clinical benefit in 10 to 15% of patients.

The dose reduction protocol after a systemic reaction follows established AAAAI/ACAAI guidelines (Cox 2011). After a Grade 1 reaction (mild — one organ system), the dose is typically reduced to approximately 50% of the reaction-causing amount, then re-escalated gradually. After a Grade 2 reaction (moderate — multiple organ systems), the dose is reduced to approximately 10% of the reaction dose. After a Grade 3 severe reaction, the dose is reduced to approximately 1% (a 10-fold dilution) and continuation of SCIT is actively reconsidered. New vials, even at the same nominal concentration, routinely prompt a 50% dose reduction due to extract potency variability. Your allergist will document the reaction grade, symptoms, timing, and interventions, then create an individualized re-escalation schedule.

In most cases, yes. The majority of patients who experience a systemic reaction during SCIT — particularly during the build-up phase — continue treatment successfully after dose reduction and re-escalation (Roy 2007, Ann Allergy). Your allergist will determine whether continuation is appropriate based on the severity of the reaction (Grade 1-2 reactions generally allow continuation; Grade 3-4 prompt more serious reconsideration), your current asthma control status, and how well your re-escalated doses are tolerated. The key consideration is whether the benefits of completing treatment outweigh the risk of another, potentially more severe reaction. For patients with multiple Grade 2-3 reactions despite careful dose adjustment, switching to sublingual immunotherapy or discontinuing treatment are both valid options to discuss.

The evidence on this question is more nuanced than often presented. The AAAAI/ACAAI Practice Parameter (Cox 2011) states that a single large local reaction does not predict the next systemic reaction — and Tankersley 2000 and Kelso 2004 both showed that dose adjustment after isolated large local reactions did not meaningfully reduce systemic reaction rates. However, the REPEAT Study (Calabria 2011) found that patients with frequent or recurrent large local reactions had a 41.7% systemic reaction rate versus 10.7% in patients without recurring local reactions. Roy 2007 found large local reactions were significantly more common in patients who went on to have systemic reactions. The bottom line: a single isolated large local reaction is not an alarming predictor, but a consistent pattern of recurrent large local reactions at multiple visits may identify a higher-risk subset worth monitoring more carefully.

Yes. Cluster allergy shot protocols compress the build-up phase from 3 to 6 months down to 4 to 8 weeks by administering 2 to 4 injections per visit. The trade-off is a higher per-injection systemic reaction rate. A 2022 Johns Hopkins study (Tversky, JACI) found that cluster protocols produced a 3.3-fold higher per-injection systemic reaction rate compared to conventional schedules (2.29% vs. 0.69%, IRR 3.3, 95% CI 1.5-7.3). A multicenter cluster cohort reported a 10.9% per-patient systemic reaction rate over the cluster period. Cluster protocols typically include antihistamine premedication, vital-sign checks between same-day injections, and extended post-injection observation periods. The faster path to maintenance is the benefit; the higher transient reaction rate is the trade-off.

Reactions to allergy shots range from very common (for local injection-site reactions) to rare (for severe systemic events). Local reactions — redness, swelling, and itching at the shot location — occur in 26 to 86% of patients receiving SCIT, depending on the definition used and the cohort studied (James and Bernstein 2017 review). Systemic reactions, involving organs beyond the injection arm, occur in approximately 0.1 to 0.2% of injection visits, or about 0.7% of patients per year, based on the AAAAI/ACAAI National Surveillance Study of over 54 million injection visits. Severe Grade 3 reactions (significant bronchospasm not responding to bronchodilator or laryngeal edema) occur at approximately 1 per 300,000 visits. Fatal reactions have become exceedingly rare at approximately 1 per 9 million visits in the most recent surveillance period (2008-2017).